Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-01-09
2007-01-09
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S183000, C544S112000, C514S231500
Reexamination Certificate
active
10420399
ABSTRACT:
Compounds having the formula (I),and pharmaceutically acceptable salts, prodrugs, and solvates thereof, are useful as kinase inhibitors, wherein R1, R2, R3, R4, R5, R6, X and Z are as described in the specification.
REFERENCES:
patent: 6147080 (2000-11-01), Bemis et al.
patent: 6251914 (2001-06-01), Adams et al.
patent: 6277989 (2001-08-01), Chakravarty et al.
patent: 6670357 (2003-12-01), Leftheris et al.
patent: 2002/0065270 (2002-05-01), Moriarty et al.
patent: 2002/0137747 (2002-09-01), Moriarty et al.
patent: 2003/0139435 (2003-07-01), Ahmed et al.
patent: 2003/0186982 (2003-10-01), Godfrey et al.
patent: 2003/0186983 (2003-10-01), Mastalerz et al.
patent: 2004/0023992 (2004-02-01), Das et al.
patent: 2004/0063707 (2004-04-01), Bhide et al.
patent: 2004/0063708 (2004-04-01), Bhide et al.
patent: 2004/0072832 (2004-04-01), Bhide et al.
patent: 2004/0077858 (2004-04-01), Bhide et al.
patent: 2004/0142931 (2004-07-01), Vite et al.
patent: WO00/20402 (2000-04-01), None
patent: WO 00/56738 (2000-09-01), None
patent: WO 00/71129 (2000-11-01), None
patent: WO 01/14378 (2001-03-01), None
patent: WO 01/27089 (2001-04-01), None
patent: WO 01/34605 (2001-05-01), None
patent: WO02/40486 (2002-05-01), None
Wolft Manfred E. “Burger's Medicinal Chemistry, 5ed, Part 1”, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al, “Modern Pharmaceutices, 3ed.”, Marcel Dekker, New York. 1996, p. 596.
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.
Henry et al., Drugs. Fut., vol. 24, pp. 1345-1354 (1999).
Rankin et al., Br. J. Rheumatol., vol. 34, pp. 334-342 (1995).
Moreland et al., Ann. Intern.Med., vol. 130, pp. 478-486 (1999).
Branger, J., et al., “Anti-Inflammatory Effects of a p38 Mitogen-Activated Protein Kinase Inhibitor During Human Endotoxemia”, The Journal of Immunology, vol. 168, pp. 4070-4077, (2002).
Davis, J. C., Jr., “Understanding the Role of Tumor Necrosis Factor Inhibition in Ankylosing Spondylitis”, Seminars in Arthritis and Rheumatism, vol. 34, pp. 668-677, (2004).
Gottlieb, A. B., et al., TNF Inhibition Rapidly Down-Regulates Multiple Proinflammatory Pathways in Psoriasis Plaques1, The Journal of Immunology, vol. 175, pp. 2721-2729, (2005).
Hideshima, T. et al, “Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu”, Blood, vol. 101(2), pp. 703-706, (2003).
Johansen, C., et al., “Protein Expression of TNF-α in Psoriatic Skin Is Regulated at a Posttranscriptional Level by MAPK-Activated Protein Kinase 21”, The Journal of Immunology, vol. 176, pp. 1431-1438, (2006).
Johansen, C., et al., “The mitogen-activated protein kinases p38 and KRK1/2 are increased in lesional psoriatic skin”, British Journal of Dermatology, vol. 152, pp. 37-42, (2005).
Kumar, S., et al., “P38 MAP Kinases: Key Signalling Molecules as Therapeutic Targets for Inflammatory Diseases”, vol. 2, pp. 717-726, (2003).
Mease, P. J., et al., “Psoriatic arthritis treatment: biological response modifiers”, Ann. Rheum. Dis., vol. 64 (Suppl. II), pp. ii78-ii82, (2005).
Navas, TA, et al., Inhibition of p38α MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-XL, MCI-1 and p53 levelsin vitroand inhibits tumor growthin vivo, Leukemia, 1-11 (2006).
Papp. K. A., “The long-term efficacy and safety of new biological therapies for psoriasis”, Arch. Dermatol. Res. vol. 298, pp. 7-15, (2006).
Saklatvala, J., “The p38 MAP kinase pathway as a therapeutic target in inflammatory disease”, Current Opinion in Pharmacology, vol. 4, pp. 372-377, (2004).
Waetzig G. H., “p38 Mitogen-Activated Protein Kinase Is Activated and Linked to TNF-α Signaling in Inflammatory Bowel Disease1”, The Journal of Immunology, vol. 168, pp. 5342-5351, (2002).
Dyckman Alaric
Hynes John
Leftheris Katerina
Liu Chunjian
Wrobleski Stephen T.
Balasubramanian Venkataraman
Bristol-Myers-Squibb Company
Korsen Elliott
Wang Joseph C.
Winslow Anastasia P.
LandOfFree
Pyrrolo-triazine aniline compounds useful as kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrrolo-triazine aniline compounds useful as kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolo-triazine aniline compounds useful as kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3746782